Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elinogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elinogrel SCHEMBL31722301 | 1.00 | P2RY12 (1.00) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| Elinogrel SCHEMBL27718842 | 0.99 | P2RY12 (0.98) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| SCHEMBL328669 | 0.93 | P2RY12 (0.87) | P2RY12MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL9922648 | 0.92 | P2RY12 (0.85) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| SCHEMBL15494787 | 0.91 | P2RY12 (0.84) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| SCHEMBL682018 | 0.91 | P2RY12 (0.84) | P2RY12MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL9922634 | 0.90 | P2RY12 (0.82) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| SCHEMBL9281504 | 0.90 | P2RY12 (0.81) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 | |
| SCHEMBL14421064 | 0.89 | P2RY12 (0.80) | P2RY12MAPTKMT2ALMNACA12 | |
| SCHEMBL9922487 | 0.88 | P2RY12 (0.78) | P2RY12MAPTFBP1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3996700-B1 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING BLEEDING | FAELKER KNUT (SE) | 2026-04-29 | — | — | EP | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| US-12419914-B2 | Thrombosomes as an antiplatelet agent reversal agent | CELLPHIRE, INC. (US) | 2025-09-23 | — | — | US | claimed |
| US-12295972-B2 | Methods using freeze-dried platelet derivative compositions for restoring hemostasis in a subject | CELLPHIRE, INC. (US) | 2025-05-13 | — | — | US | claimed |
| US-12208122-B2 | Methods of treating bleeding in a subject treated with an antiplatelet agent | CELLPHIRE, INC (US) | 2025-01-28 | — | — | US | claimed |
| US-20240408141-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING A SUBJECT TAKING AN ANTI-PLATELET AGENT | CELLPHIRE, INC. (US) | 2024-12-12 | — | — | US | claimed |
| US-20240277771-A1 | METHODS OF TREATING BLEEDING IN A SUBJECT TREATED WITH AN ANTIPLATELET AGENT | CELLPHIRE, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| EP-4294411-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET-INDUCED COAGULOPATHY | Cellphire Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20220257639-A1 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING ACUTE BLEEDING COMPLICATIONS DURING/AFTER SURGERY | FÄLKER, Knut (SE) | 2022-08-18 | — | — | US | claimed |
| EP-4013496-A1 | THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT | Cellphire Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220168353-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET INDUCED COAGULOPATHY | CELLPHIRE INC. (US) | 2022-06-02 | — | — | US | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| EP-3996700-A1 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING BLEEDING | Fälker, Knut (SE) | 2022-05-18 | — | — | EP | claimed |
| EP-3993876-A1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | Tonix Pharma Limited (IE) | 2022-05-11 | — | — | EP | claimed |
| CN-114423785-A | anti-CD 154 antibodies and uses thereof | 通尼克斯制药有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-2646434-A1 | PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF | Novartis AG (CH) | 2013-10-09 | — | — | EP | claimed |
| US-20130252979-A1 | PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF MULA (I), AND METHODS OF USE THEREOF | PORTOLA PHARMACEUTICALS, INC. | 2013-09-26 | — | — | US | claimed |
| WO-2012072824-A1 | PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2012-06-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252979-A1 | PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF MULA (I), AND METHODS OF USE THEREOF | P2RY12, P2RY14, P2RY11 | P2RY12 1/4885MAPT 879/4885FBP1 1698/4885 |
| US-20220257639-A1 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING ACUTE BLEEDING COMPLICATIONS DURING/AFTER SURGERY | ICAM1, PTGIR, VCAM1 | P2RY12 67/4885MAPT 4009/4885FBP1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.